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Tyrosine kinase inhibitors for the treatment of fibrotic diseases
such as systemic sclerosis: towards molecular targeted therapies
Abstract
Systemic sclerosis (SSc) is a fibrosing connective tissue disease with significantly increased mortality.
Therapeutic options to treat fibrosis are limited. The small molecule tyrosine kinase inhibitor imatinib
and related drugs such as dasatinib and nilotinib target simultaneously two of the major profibrotic
pathways, TGFbeta- and PDGF- signaling. Imatinib, dasatinib and nilotinib inhibit collagen synthesis in
cultured fibroblasts and have potent anti-fibrotic effects in animal models of different fibrotic diseases.
Moreover, several case reports, case series and uncontrolled studies on patients with SSc, mixed
connective tissue disease, nephrogenic systemic fibrosis and in particular sclerodermatous graft versus
host disease (cGvHD) report regression of fibrosis and good tolerability. However, the results of larger
controlled trials, which are currently ongoing, are needed before any conclusions on efficacy and
tolerability can be drawn. Until the results of these trials are available, we discourage off-label use of
Imatinib in single patients.
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ABSTRACT
Systemic sclerosis (SSc) is a fibrosing connective tissue
disease with significantly increased mortality. Therapeutic
options to treat fibrosis are limited. The small molecule
tyrosine kinase inhibitor imatinib and related drugs such
as dasatinib and nilotinib target simultaneously two of the
major profibrotic pathways, TGFb- and PDGF- signaling.
Imatinib, dasatinib and nilotinib inhibit collagen synthesis
in cultured fibroblasts and have potent anti-fibrotic effects
in animal models of different fibrotic diseases. Moreover,
several case reports, case series and uncontrolled studies
on patients with SSc, mixed connective tissue disease,
nephrogenic systemic fibrosis and in particular sclero-
dermatous graft versus host disease (cGvHD) report
regression of fibrosis and good tolerability. However, the
results of larger controlled trials, which are currently
ongoing, are needed before any conclusions on efficacy
and tolerability can be drawn. Until the results of these
trials are available, we discourage off-label use of Imatinib
in single patients.
Systemic sclerosis (SSc) is a chronic disorder of the
connective tissues that affects the skin and internal
organs, including the lungs, kidneys, heart and
gastrointestinal tract. Histological hallmarks in the
skin of early stages of SSc are perivascular inflam-
matory infiltrates and microvascular changes such as
capillary dilatation with subsequent rarefaction. In
later stages, this leads to tissue fibrosis with an
excessive accumulation of extracellular matrix.1
Tissue fibrosis disrupts the physiological tissue
architecture and leads to dysfunction of the affected
organs. Tissue fibrosis causes not only significant
morbidity but, together with vascular manifesta-
tions such as pulmonary arterial hypertension, is
also the major cause of death in patients with SSc.2
With pulmonary arterial hypertension and (lung)
fibrosis accounting for up to 70% of SSc-related
causes of death, the need for intensive preclinical and
clinical research in these areas is clear. Herein, we
focus on the molecular mechanisms of fibrosis and
potential molecular targets for therapy.
The overproduction of extracellular matrix
(ECM) components in patients with SSc is
mediated by activated fibroblasts, which produce
increased amounts of different types of ECM
proteins such as glycosaminoglycans, fibronectins
and collagens.1 The molecular mechanisms leading
to tissue fibrosis are incompletely understood and
the cause or trigger of SSc is unknown. However,
remarkable advances have been made in the
identification of key mediators and their intracel-
lular signalling cascades.3 Interestingly, similar
mechanisms also account for other fibrotic diseases
such as graft-versus-host disease.4 These findings
have direct translational implications, because
drugs targeting these pathways are often in clinical
use in other diseases. This review summarises the
clinical and preclinical evidence of imatinib and
other tyrosine kinase inhibitors targeting c-abl and
platelet-derived growth factor (PDGF) receptors as
novel antifibrotic treatment approaches in SSc.
RATIONALE BEHIND TYROSINE KINASE
INHIBITORS AS AN ANTIFIBROTIC THERAPY
Imatinib mesylate (STI571, Gleevec/Glivec, Novartis
Basel, Switzerland) is a small molecule tyrosine
kinase inhibitor that binds to the ATP-binding
pocket of abelson kinase (c-abl) and efficiently blocks
its tyrosine kinase activity. Thus, target proteins of
c-abl are no longer phosphorylated, and downstream
effects of these activated target proteins, such as
proliferation and anti-apoptotic effects, are blocked.
c-abl by itself is an important downstream signalling
molecule of transforming growth factor b (TGFb).5
In cells deficient for c-abl, the induction of ECM
proteins by TGFb is strongly decreased. In addition
to its effects on c-abl, imatinib interferes with PDGF
signalling by blocking the tyrosine kinase activity of
PDGF receptors. Imatinib inhibits also the tyrosine
kinase activity of the gene product of the proto-
oncogene c-kit and c-fms.6 7 Thus, imatinib mesylate
targets simultaneously and rather selectively two
major profibrotic pathways activated in SSc.
Besides its selectivity, favourable pharmacoki-
netics, long-standing clinical experience with ima-
tinib in other indications and an acceptable profile
of adverse effects provide an argument for the use
of imatinib. Imatinib is an orally administered
drug, that is readily absorbed and has to be taken
only once daily, because of its long half-life of 13–
16 h.7 Imatinib is currently widely used for the
treatment of bcr-abl positive chronic myelogenous
leukaemia and gastrointestinal stromal tumours,
with more 100 000 patients treated so far. Previous
clinical trials on patients with chronic myelogen-
ous leukaemia have suggested that imatinib is well
tolerated with severe adverse side effects leading to
discontinuation of the drug in ,1% of patients in
this indication. However, mild to moderate side
effects are common and outside clinical trials, up to
one-quarter of patients discontinue imatinib because
of adverse effects. The major adverse events respon-
sible for discontinuation are dose dependent and
include oedemas, muscle cramps and creatine kinase
elevations, uncontrollable diarrhoea and bone mar-
row toxicity.8 9 Furthermore, abl-kinase inhibitors
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might induce congestive heart failure, although the number of
reported patients is low and most patients had pre-existing
cardiac disease or a variety of cardiovascular risk factors.
Nevertheless, these adverse effects need particular attention in
clinical trials with patients with SSc because cardiac involvement
is common in patients with SSc. The gastrointestinal tract is one
of the most frequent organ manifestations in SSc, including
intermittent diarrhoea, because of small bowel bacterial over-
growth, and a significant number of patients have coexisting
myositis with creatine kinase elevations. In addition, mild to
moderate oedema might be less well tolerated by patients with
SSc with existing skin diseases than by patients with cancers.
PRECLINICAL EVIDENCE OF THE ANTIFIBROTIC EFFECTS OF
IMATINIB
Incubation of cultured fibroblasts from patients with SSc and
healthy volunteers with imatinib strongly inhibited the synth-
esis of col 1a1, col 1a2 and fibronectin-1 on the mRNA as well as
protein level by up to 90% at concentrations of 1.0 mg/ml.10 No
changes of the expression of tissue inhibitors of metalloprotei-
nase and matrix metalloproteinases were seen that might have
counterbalanced the decreased production of ECM proteins.
Furthermore, treatment with imatinib completely prevented
the development of fibrosis in the mouse model of bleomycin-
induced dermal fibrosis. Treatment of mice with imatinib at
doses of 50 mg/kg/day and 150 mg/kg/day had strong anti-
fibrotic effects without toxic side effects. Imatinib prevented
the differentiation of resting fibroblasts into myofibroblasts and
dose dependently reduced the synthesis and accumulation of
ECM in lesional skin. Imatinib also exerted potent antifibrotic
effects in the tight-skin-1 (tsk-1) mouse model of SSc.11
Bleomycin-induced fibrosis is characterised by a strong infiltra-
tion of leukocytes with secondary activation of fibroblasts and
resembles early, inflammatory stages of SSc. In contrast,
fibroblasts isolated from tsk-1 mice show an endogenous
activation with increased release of ECM and tsk-1 mice are
used as a model system to mimic later stages of SSc. Treatment
of tsk-1 mice with imatinib in doses of 150 mg/kg/day
significantly reduced hypodermal thickening and differentiation
of resting fibroblasts into myofibroblasts, and ameliorated the
tsk-1 phenotype.11 In addition to experimental models of SSc,
imatinib was also effective in different models of pulmonary,
renal and liver fibrosis.5 12–14
In addition to prevention of fibrosis, imatinib might also be
effective for the treatment of established fibrosis. We demon-
strated recently that imatinib induces regression of pre-
established fibrosis in a modified model of bleomycin-induced
dermal fibrosis.11 Treatment with imatinib started 3 weeks after
injection with bleomycin not only stopped further progression
of dermal fibrosis despite ongoing challenge with bleomycin but
also reduced dermal thickening to levels below that seen after
3 weeks of bleomycin. Thus, imatinib not only prevented
progression but also induced regression of fibrosis. This is
probably owing to the potent reduction of the synthesis of the
ECM, which shifts the balance between synthesis of ECM and
degradation of ECM towards degradation.
Of note, the concentrations used in our study for the
treatment of mice produce serum levels of imatinib similar to
those found in humans with standard doses of 400–800 mg
imatinib per day per os, because of a faster metabolisation of
imatinib in mice. Similarly, the concentration of 1.0 mg/ml
imatinib used in vitro is below the mean serum concentrations
found in humans.5 7
FIRST CLINICAL REPORTS ON THE EFFECTS OF IMATINIB ON
FIBROSIS
The first clinical evidence for an antifibrotic effect of imatinib
came from patients with chronic myelogenous leukaemia (CML)
and concomitant bone marrow fibrosis. Two small clinical studies
suggested that treatment of patients with CML with imatinib
might lead to a regression of bone marrow fibrosis.15 16 Of note,
the antifibrotic effect did not correlate with the cytogenetic
response, suggesting an effect independent from the suppression
of Philadelphia chromosome-positive cancer cells.16
Meanwhile, several case reports and small case series have
reported on the efficacy and safety of imatinib in patients with
SSc and other fibrosing connective tissue diseases.
We reported the successful treatment of pulmonary fibrosis
with imatinib in a patient with anti-U1-antibody-positive
mixed connective tissue disease.17 Before initiation of imatinib,
the patient rapidly deteriorated despite treatment with cortico-
steroids and immunosuppressant agents. However, during a
20-week trial with 400 mg/day imatinib, the patient progres-
sively improved. The New York Heart Association (NYHA)
class changed from NYHA IV to NYHA II. The 6 min walking
distance increased by 50 m and the carbon monoxide transfer
factor increased from 26% predicted to 45% predicted. The
arterial oxygen pressure increased from 64 mm Hg to 70 mm
Hg at rest and from 50 mm Hg to 62 mm Hg after exertion.
Ground-glass opacities decreased during treatment, whereas the
reticular changes remained constant. However, no changes in
forced vital capacity and total lung capacity were seen. The
patient tolerated the treatment well and did not experience any
adverse events apart from mild oedema.
Kay and High reported impressive responses of two patients
with nephrogenic systemic fibrosis treated with imatinib in doses
of 400 mg/day.18 In the first patient, the modified Rodnan skin
score (mRSS) decreased from 42 to 16 within 15 weeks. In the
second patient, a decrease of the mRSS from 12 to 2 occurred
within 12 weeks. In parallel with the mRSS, reduced accumula-
tion of the ECM and decreased expression of type I procollagen
was seen in skin biopsy specimens of these patients. Of note, skin
thickening rapidly reoccurred in both patients within a few weeks
of stopping imatinib, probably because of the persistent
accumulation of gadolinium. However, the fibrotic changes
regressed again upon reintroduction of imatinib.
Similar successful case reports and case series with imatinib
have been reported for patients with treatment-resistant
SSc.19 20 In general, skin fibrosis appeared to be more responsive
than lung fibrosis in these case series.21 Chung et al reported
beneficial effects in two patients with SSc treated with imatinib
at doses of 200 mg/day.22 The first patient was diagnosed with
SSc 3 years before and deteriorated with progressive pulmonary
and dermal fibrosis despite treatment with cyclophosphamide.
After 3 months treatment with imatinib, the mRSS decreased
from 36 to 21 and pulmonary disease stabilised. The second
patient was newly diagnosed with SSc and imatinib was
initiated owing to intolerance of other therapeutic approaches.
Within the 6 months of receiving imatinib, her mRSS decreased
from 36 to 20. Both patients tolerated imatinib well and no
major side effects were reported. Chang and coworkers
performed molecular analyses on skin biopsy specimens taken
from both patients before and after treatment with imatinib.
They demonstrated that PDFG receptor and c-abl were
phosphorylated and thereby activated in lesional skin before
treatment and that imatinib strongly decreased the phosphor-
ylation of both targets.22 Moreover, they identified an imatinib-
responsive signature specific to diffuse SSc by gene expression
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profiling, suggesting that imatinib targets a gene expression
programme that is dysregulated in diffuse SSc.
Additional evidence for an antifibrotic effect of imatinib
comes from two recent studies reporting on the effects of
imatinib on the refractory sclerodermatous graft-versus-host
disease (cGvHD).23 24 cGvHD is a rather common adverse event
after allogeneic stem cell transplantation. Similar to SSc and
other fibrotic treatments, current therapeutic approaches are
unsatisfactory and the mortality of affected patients is high.
Sclerodermatous cGvHD shares many clinical features with SSc
and mice undergoing bone marrow transplantation with a
minor HLA mismatch resulting in murine sclerodermatous
cGvHD are often used as a murine model of SSc.25–28
One study reports on 19 patients with refractory cGvHD for
whom at least two previous treatment approaches had failed.24
The organs involved were skin in 17 patients, lungs in 11
patients and bowel in 5 patients. The doses of imatinib given in
this study were relatively low and ranged from 50 to 200 mg/
day. The rate of imatinib-related severe adverse events was
acceptable and imatinib was discontinued in three patients
owing to toxicity. Imatinib was discontinued in an additional
three patients owing to a lack of efficacy and in two patients
owing to relapse of malignancy. The response rates were
remarkable with seven complete remissions and eight partial
remissions, defined as at least 50% improvement after
6 months. Skin fibrosis, as analysed by the mRSS, improved
in all but two patients with a mean reduction from 38 (range
18–51) to 8 (range 0–36) after 6 months of treatment. Similarly,
lung function scores improved in seven out of 11 patients and
remained stable in the other four patients.
The other study reported on the treatment of 14 patients
with refractory cGvHD.23 The doses of imatinib in this study
were higher, with the majority of patients taking 400 mg
imatinib a day. Four patients had to discontinue imatinib owing
to drug intolerance. Seven patients responded to imatinib with
an improvement of the mRSS of .90% in four of them
including two patients with complete resolution of any
clinically assessable skin fibrosis. The authors also noted a
significant reduction of the corticosteroid dosage.
Although both trials were uncontrolled and non-blinded, the
regression of the fibrotic changes in imatinib-treated patients
with sclerodermatous cGvHD is impressive and suggests that
imatinib might be effective for the treatment of scleroderma-
tous cGvHD.
OTHER TYROSINE KINASE INHIBITORS OF C-ABL AND PDGF
RECEPTOR
Recently, dasatinib (Sprycel, Bristol-Myers-Squibb, New York,
New York, USA) and nilotinib (Tasigna, Novartis), two novel
inhibitors of abl-kinases and PDGF receptors have been
approved for the treatment of bcr-abl positive CML with
resistance or intolerance to imatinib. Dasatinib and nilotinib are
small-molecule tyrosine kinase inhibitors, which can be
administered orally.29–33 Like imatinib, nilotinib selectively
inhibits the tyrosine kinase activity of abl-kinases, PDGF
receptor and c-kit. Dasatinib is less selective and inhibits
additionally the structurally related family of src-kinases.31
Both, dasatinib and nilotinib inhibit the activity of abl-kinases
much more potently than imatinib and are effective in most cell
lines resistant to imatinib.34 The spectrum of adverse effects of
dasatinib and nilotinib differs from that of imatinib and
patients with intolerance to imatinib can often be switched
safely to nilotinib or dasatinib.30 35–37 Thus, dasatinib and
nilotinib might be interesting candidates for the treatment of
patients who cannot tolerate imatinib. Indeed, incubation of
cultured fibroblasts with dasatinib or nilotinib potently
decreased the synthesis of ECM proteins without compensatory
changes of the tissue inhibitors of metalloproteinase or matrix
metalloproteinases.38 Furthermore, treatment of mice with
dasatinib or nilotinib dose dependently reduced the devolve-
ment of dermal fibrosis in the mouse model of bleomycin-
induced dermal fibrosis. Thus, dasatinib and nilotinib might be
interesting alternatives to imatinib.
CONCLUSION
Mortality is significantly increased in SSc. Despite extensive
research, therapeutic options for antifibrotic treatments are very
limited. So far, a significant antifibrotic effect has only been
demonstrated for cyclophosphamide, but the effect is mild at
best and treatment with cyclophosphamide is accompanied by a
significant toxicity. Preclinical data suggest that the small-
molecule inhibitor imatinib and related drugs such as dasatinib
and nilotinib, which target selectively and simultaneously TGFb
and PDGF signalling pathways, have potent antifibrotic effects.
First case reports, case series and uncontrolled studies on
patients with SSc, mixed connective tissue disease, nephrogenic
systemic fibrosis and, in particular, sclerodermatous cGvHD are
promising. However, at least for SSc, the course of the disease is
variable with spontaneous regression of dermal fibrosis in
several patients. Thus, the reported regression of fibrosis might
reflect the spontaneous course of the disease in individual
patients and not a response to imatinib. In addition, the
possibility of a publication bias cannot be excluded, as long,
controlled and/or prospective studies are not available.
An appropriate assessment of toxicity is necessary in a larger
number of patients to exclude relevant adverse effects in
patients with SSc, who frequently have SSc-related cardiac
pathologies. In addition, gastrointestinal side effects and
myalgias might be more common in patients with SSc because
of gastrointestinal and muscular involvement in this disease.
Oedema might also be more common and more severe in
patients with SSc owing to pre-existing microangiopathy.
It needs to be strongly emphasised that no definite conclusions
about safety and efficacy can be drawn from the published reports
and that the safety and efficacy of imatinib can only be
investigated in larger controlled clinical trials that are currently
ongoing (see http://www.clinicaltrials.gov (accessed 1 September
2009) for details). We recommend the inclusion of patients in
larger clinical trials and strictly discourage uncontrolled off-label
use of imatinib or other tyrosine kinase inhibitors in single
patients, until the toxicity profile has been established or the
results of the ongoing clinical trials are available.
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